BioLineRx Ltd Asset Resilience Ratio

Latest as of June 2026: 25.24%

BioLineRx Ltd asset resilience ratio. BioLineRx Ltd (BLRX) has an Asset Resilience Ratio of 25.24% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BioLineRx Ltd (BLRX) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$8.45 Million

Cash + Short-term Investments

Total Assets

$33.48 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of BioLineRx Ltd (2008–2025)

Asset resilience ratio of BioLineRx Ltd from 2008 to 2025. This chart shows how BioLineRx Ltd's Asset Resilience Ratio has changed over time. Read BioLineRx Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down BioLineRx Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of BioLineRx Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$8.45 Million	25.24%
Total Liquid Assets	$8.45 Million	25.24%

Asset Resilience Insights

Very High Liquidity: BioLineRx Ltd maintains exceptional liquid asset reserves at 25.24% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

BioLineRx Ltd Industry Peers by Asset Resilience Ratio

Compare BioLineRx Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Hyloris Developmentsen Sa BR:HYL	Biotechnology	1.36%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Oruka Therapeutics, Inc. NASDAQ:ORKA	Biotechnology	53.11%
Gempharmatech Co. Ltd. A SHG:688046	Biotechnology	23.95%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%
Inventiva S.A PA:IVA	Biotechnology	52.73%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%
Guangdong VTR Bio-Tech Co Ltd SHE:300381	Biotechnology	4.98%

BioLineRx Ltd Asset Resilience Ratio by Year (2008–2025)

BioLineRx Ltd asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for BioLineRx Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	43.09%	$17.63 Million	$40.90 Million	+19.63pp
2024-12-31	23.46%	$9.13 Million	$38.91 Million	-37.14pp
2023-12-31	60.60%	$38.74 Million	$63.92 Million	+7.59pp
2022-12-31	53.02%	$40.49 Million	$76.38 Million	-1.22pp
2021-12-31	54.24%	$44.15 Million	$81.39 Million	+42.07pp
2020-12-31	12.17%	$5.76 Million	$47.29 Million	-29.26pp
2019-12-31	41.43%	$22.19 Million	$53.57 Million	-6.14pp
2018-12-31	47.56%	$26.75 Million	$56.23 Million	-25.22pp
2017-12-31	72.78%	$44.37 Million	$60.97 Million	-12.36pp
2016-12-31	85.14%	$33.15 Million	$38.94 Million	+3.04pp
2015-12-31	82.10%	$42.12 Million	$51.30 Million	+2.32pp
2014-12-31	79.78%	$28.85 Million	$36.17 Million	+33.22pp
2013-12-31	46.56%	$9.29 Million	$19.95 Million	+33.94pp
2012-12-31	12.62%	$3.07 Million	$24.31 Million	-46.29pp
2011-12-31	58.91%	$17.28 Million	$29.34 Million	+40.78pp
2010-12-31	18.13%	$7.92 Million	$43.66 Million	-8.56pp
2008-12-31	26.69%	$8.18 Million	$30.64 Million	--

pp = percentage points

About BioLineRx Ltd

NASDAQ:BLRX USA Biotechnology

Market Cap

$9.26 Million

Market Cap Rank

#27132 Global

#5642 in USA

Share Price

$1.91

Change (1 day)

-2.55%

52-Week Range

$1.91 - $3.78

All Time High

$24.30